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Introduction
Sensitive detection and accurate analysis of protein biomarker molecules are absolutely essential for the early detection, treatment and management of many diseases. In addition the recognition of disease biomarker patterns has a significant role to play in future disease prevention. [1, 2] Current approaches to biomarker detection typically involve ELISA or sandwich type immunoassays coupled with fluorescent or electrochemical detection. In addition electrochemiluminescence (ECL) based systems such as that developed by Roche have been commercialised and are currently used by clinicians worldwide for the detection of protein biomarkers. Sandwich-type immunoassays for biomarker detection typically employ a capture antibody immobilised on a surface that selectively enriches the concentration of target antigen at the sensor surface. A labeled secondary antibody then binds to the captured antigen and facilitates quantitative measurement of the analyte concentration. Common issues with ELISA based assays include sensitivity and specificity issues primarily caused by non-specific in addition to sub-optimal antibody orientation on the surface. In addition the challenges of immobilising heavy chain antibodies of approximately 80 kDa to biosensor transduction platforms also persist. Recent advances in antibody engineering have enabled the development of low molecular weight single chain fragment variable (scFv) antibodies. [3, 4] . Primarily due to their reduced size and high specificity there has been much interest in 
Electrochemiluminescent detection of C-Reactive protein
CRP is an acute phase reactant in the inflammation response and one of a growing number of cardiac risk biomarkers that are used to determine a person's risk of developing cardiovascular disease (CVD). While CRP is an indicator of inflammation, its presence at elevated levels is associated with an increased risk of stroke and myocardial infarction, [7] therefore, its accurate detection is of significant importance to clinicians and medical practitioners alike. Current clinical testing methods suffer from a relative lack of sensitivity with cut off limits of 3 -5µg mL -1 . High Sensitivity CRP (hs-CRP) ELISA-based testing kits with sensitivities of 3 pg mL -1 are now commercially available (Abcam). As previously stated the high sensitivity and low background signals of ECL biosensors are well documented [8, 9] and it was therefore anticipated that the incorporation of the significantly smaller yet highly specific scFv antibody fragments into an ECL-based cardiac biosensor would enhance detection limits due to (a) a higher concentration of capture antibody on the electrode surface (b) more capture antibodies having the correct surface orientation and (c) a reduction in non-specific binding due to the absence of a full length antibody. In addition, ECL-based systems offer the ability to tailor ECL probe materials for multiple analyte detection. A schematic of the developed assay can be seen in Scheme 1. Recombinant scFv antibodies with high affinity for monomeric C-Reactive Protein (mCRP KD -3.53 x 10 -10 M) [10] were purified and were then immobilised on a Pt electrode surface followed by absorption and subsequent capture of pentameric CRP (pCRP) in solution during a 20 minute timeframe. The high affinity of the scFv antibodies for C-Reactive protein ensured binding of both sizable and minute concentrations of the analyte protein to the electrode surface. The bound pCRP was then detected by ECL using the same recombinant scFv antibody fragment covalently labelled with the luminescent metal probe [Ru(bpy)2PICNH2] 2+ . Labeling of the luminescent metal probe was examined by spectroscopy, with solutions of labeled antibody producing absorption and emission profiles typical of the ruthenium metal probe (Supplementary data, Figure S1 ). The ECL assay procedure was carried out as previously described using tripropylamine (TPA) as a co-reactant. The electrocatalytic oxidation of TPA by ruthenium metal centres is a common mechanism which can result in the production of an ECL response when the oxidised co-reactant (TPA) and the oxidised ruthenium metal centre of the label react. [11, 12] Figure 1 shows the dependence of ECL emission over a CRP concentration range (5 fg mL -1 to 600 ng mL -1 ). The ECL emission observed at 1.2 V versus a silver/silver chloride (Ag/AgCl) reference electrode, corresponds with previous reports for a ruthenium metal centre and the shape of the curve is in accordance with ruthenium based ECL dynamics. The peak currents correspond to the electrocatalytic oxidation of TPA, (tri-n-propylamine) by the ruthenium label covalently attached to the anti-CRP scFv fragment. The absence of an ECL signal at 0.8 V illustrates that the ECL mechanism does not involve the "revisited route", where TPA radicals diffuse and react directly with [Ru(bpy)3] 2+ to generate the excited state. The ECL signal observed at 1.2 V vs. Ag/AgCl is exclusive of the oxidation potential of TPA. The distance between adjacent redox sites is a key factor governing the efficiency of the electron-transfer processes. It is equivalent to the charge diffusion in redox polymers involving an electronhopping process from site to site where transport of both electrons and charge compensating counter ions occurs simultaneously. [11, 13] The rate of electron transfer k decays exponentially with the distance r between redox centres in the transition state. A bimolecular rate of electron transfer for Ru 2+ * to Ru 3+ of ~10 6 M -1 s -1 was reported previously, highlighting the fact that the excited state can be quenched efficiently by Ru 3+ species in close proximity to the excited state Ru 2+ *. [13, 14] Although electron-hopping may be possible between adjacent ruthenium centres, given the extremely low levels of label present on the electrodes due to the low levels of antigen present, it is unlikely that the assay is affected by this phenomena. ECL production, however, is highly dependent upon the rate of charge transfer (DCT). A fast rate of charge transfer ensures sufficient Ru 3+ will be present to react with a given analyte and produce ECL. An insufficient amount of Ru 3+ will result in decreased ECL emission and hence decreased sensitivity. The DCT value for the [Ru(bpy)2PICH2] 2+ is typical of Ru 2+/3+ systems, yielding a value of ~10 9 cm -1 s -1 consistent with previously published work. [10, [12] [13] [14] This value suggests that despite the minute concentrations of ruthenium label present, charge transfer via diffusion is not a limiting factor for the assay thereby further highlighting the suitability of ECL as a transduction mechanism for this assay. The voltammetric behavior of [Ru(bpy)2PICH2] 2+ and the Randles-Sevçik plots are supplied in the supplementary material, Figure S2 .
A wide variety of hsCRP assays are currently available commercially with linear ranges from 0.1 mg to 10 mg /L, and as such are sufficiently sensitive to measure the vast majority of patients presenting at a clinic. As such the bio-sensor herein was developed not as a replacement for such systems but to demonstrate the potential advantages of combining scFv antibody technology with ECL from the perspective of sensitivity, cost of production, response time and robustness. Figure 1 (inset) , shows the dependence of the logarithm of the maximum ECL intensity on log[CRP] over a clinically significant range. The maximum value of 600 ng mL -1 corresponds to 0.6 mg L -1 , which is within the clinical range for low risk levels of CRP. Of significantly more interest is the lower limits of detection possible with this approach. The analytical sensitivity or limit of detection (LOD) was calculated using the formula [Average ECL emission of the blank + 3SD (blank)]. The LOD for the assay was calculated to be 0.3 fg mL -1 considerably lower than the pg mL -1 detection limits of current commercially available CRP testing kits or the ng ml -1 LODs obtained by electrochemical detection [14, 15] . The limit of quantification (LOQ) for the assay was calculated to be approximately 2 fg mL -1 . While the clinical relevance of these figures may be limited to CRP concentrations typically occurring at pg mL -1 levels, if applied correctly the approach has the potential to improve current techniques for the monitoring of other myocardial infarction biomarkers such as Troponin T which are currently undetectable by conventional assays at sub 10 pg mL -1 concentrations. It is for applications such as this that the authors envisage the newly developed assay offers the most potential from a clinical perspective. While sensitivity is of immense importance in biosensor design, its significance is surpassed only by selectivity. While antibody/antigen interactions possess a high degree of specificity this is often negated by an inaccurate transduction process, often leading to the production of a false positive. To further validate the new strategy's utility and specificity a series of controls were designed and analyzed experimentally. Figure  2 shows the ECL response obtained for incomplete variants of the sandwich assay. The ECL signal circa 1.2 V was only observed when the complete sandwich assay was tested and indicates that a positive result is only observed in the presence of C-reactive protein. To assess variability parameters of the assay the results were performed using a sample size of n =3 on n=3 days. Figure 3 shows the averaged ECL response for 3 separate assays conducted in three consecutive days. In each case the CRP antigen concentration was 5 fg mL -1 . Given the low quantity of analyte present some variability in the detection signal was expected, however, the associated standard deviation was calculated to be ~ 7 x 10 -5 indicating excellent inter-electrode reproducibility. To assess the long term stability of the sensor ECL measurements were performed over 21 days (S3 supplementary material). During this timeframe an overall reduction in ECL intensity of 4.8% was recorded, corresponding favourably with previously reported stability data for Ru(bpy)3 2+ based ECL sensing platforms. [16, 17] Previous work has shown that these scFv recombinant antibodies are extremely efficient at selectively discerning specific CRP antigens from other competing antigens. [18] Although not examined directly within this study, this previous work highlights the utility of this assay in selectively detecting CRP over the biological relevant concentration range. Due to the inherent nature of ECL no photonic excitation source is required thereby resulting in a significant cost saving and reduced background interference in comparison to UV and traditional fluorescent based detection systems. In addition, the lower costs associated with the production of recombinant antibodies compared to traditional antibody production methods involving vertebrate hosts ensure that the developed sensor is a promising platform for future point of care health monitoring.
Conclusions
In summary, this work highlights a proof-of-concept example for a new, robust and feasible ECL sensor for the determination of CRP with high sensitivity. We have combined recombinant antibody technology with ECL for the first time to produce a powerful assay for the determination of the cardiac biomarker C-Reactive protein at the fg level, which to our knowledge is the first reported sensor capable of detecting CRP at these detection levels. More importantly, this example paves the way for a broader application of recombinant antibody engineering across other biologically relevant biomarkers and we are currently pursuing this possibility. The authors anticipate that in combining recombinant antibody engineering with low background detection techniques such as ECL, there exists much potential for the development of a new generation of sensitive, selective and rapid biosensor as well a significant scope for the improvement of existing systems, all with a common goal of improving point-of-care health monitoring. 
Notes

